Silence Therapeutics (SLN) to Release Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is projected to post its Q2 2025 results before the market opens on Thursday, August 21st. Analysts expect Silence Therapeutics to post earnings of ($0.2067) per share and revenue of $3.3830 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2025 earningoverview page for the latest details on the call scheduled for Thursday, August 7, 2025 at 7:30 AM ET.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.27). The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $8.50 million. Silence Therapeutics had a negative net margin of 294.20% and a negative return on equity of 67.48%. On average, analysts expect Silence Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $5.52 on Wednesday. The firm’s 50-day moving average price is $5.83 and its 200-day moving average price is $4.71. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $20.48.

Institutional Investors Weigh In On Silence Therapeutics

A hedge fund recently bought a new stake in Silence Therapeutics stock. Massar Capital Management LP acquired a new position in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 19,863 shares of the company’s stock, valued at approximately $115,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Morgan Stanley lowered their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, May 9th. Wall Street Zen downgraded shares of Silence Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, June 13th. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 price target on shares of Silence Therapeutics in a research report on Friday, August 8th. Finally, The Goldman Sachs Group lowered their price target on shares of Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a research report on Friday, May 9th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.83.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.